Cytochrome P-450 2D6 and 2C19 polymorphisms and consumption of care in psychiatric practice
Van Der Baan, Frederieke H.; Gregoor, Jochem G.; Loovers, Harriët M.; Klungel, Olaf H.; Egberts, Toine C.G.; Grobbee, Diederick E.; Knol, Mirjam J.; Van Der Weide, Jan
(2011) Pharmacoepidemiology and Drug Safety, volume 20, issue S1, pp. S6 - S7
(Abstract)
Abstract
Background: Cytochrome P-450 2D6 (CYP2D6) and 2C19 (CYP2C19) are known to contain functional polymorphisms that can alter the metabolic rate of many antidepressants (AD) and antipsychotics (AP). Individuals with no metabolic activity and with increased activity may be at risk for an unsatisfactory drug response. Objectives: Aim of this study
... read more
was to assess the influence of CYP2D6 and CYP2C19 phenotypes on the consumption of care in psychiatric patients. Methods: The study was conducted in a psychiatric hospital in the Netherlands, including all admissions from July 2001 until July 2010, of patients genotyped for (at least) the CYP2D6 ∗3 ∗4 and gene multiplication and CYP2C19 ∗2. Patients were classified as poor metabolizers (PM), ultrarapid metabolizers (UM), intermediate metabolizers (IM) and extensive metabolizers (EM). To study the consumption of care, several outcome measures were calculated for PM and UM and compared to EM. Results: 7377 admissions were analyzed, belonging to 3859 unique patients. The total duration of hospital stays with AP and/or AD treatment was longer for CYP2D6 UM than for CYP2D6 EM (66 versus 48 days, p
show less
Download/Full Text
Embargo until January 01 2050
Keywords: cytochrome P450, antidepressant agent, biperiden, risk management, pharmacoepidemiology, human, patient, mental patient, prescription, metabolic rate, hospitalization, drug response, phenotype, mental hospital, Netherlands, gene, drug therapy, drug monitoring, risk
ISSN: 1053-8569
Publisher: John Wiley and Sons Ltd
See more statistics about this item